Explainer · UK

Glucomannan and the "weight loss pill" ads: what the ASA ruled, and what the fibre actually does

The ASA has ruled against Voy, Juniper and MedExpress ads that read as promoting the prescription-only Wegovy tablet, two of them for a glucomannan supplement. What the rulings say, what glucomannan does in trials, and how to spot these ads.

Review type: research summary. This page summarises published research and product labels, cited below.

On 4 November 2026 the Advertising Standards Authority (ASA) upheld four rulings against weight-loss ads from three online pharmacies: two Voy ads for a glucomannan supplement, a Juniper YouTube ad and a MedExpress Instagram story. In each case the ASA concluded that the ad promoted a prescription-only medicine to the public, which the UK advertising code does not allow. The medicine in question was the semaglutide (Wegovy) tablet, the first GLP-1 weight-loss tablet licensed in the UK.

Short answer: a plain white pill and a line such as "The weight is over" or "The weight loss pill is here" can be read as an ad for a prescription medicine, even when the small print names a food supplement. Glucomannan, the konjac fibre in two of the ads, is a lawful supplement with an authorised weight-loss claim, but trials show at best a small effect. It is not a substitute for, or a version of, a GLP-1 medicine.

Why the oral Wegovy tablet matters here

The Medicines and Healthcare products Regulatory Agency (MHRA) approved the semaglutide (Wegovy) tablet for weight loss and weight management on 11 June 2026. It may be prescribed, alongside a reduced-calorie diet and more physical activity, to adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related comorbidity. The MHRA said it is a prescription-only medicine and was not available on the NHS at approval, with NHS use to follow a NICE evaluation. The ASA rulings record that private availability followed in July 2026.

In the OASIS 4 trial (NEJM, 2025), adults without diabetes who took 25 mg oral semaglutide once a day, plus lifestyle interventions, lost an estimated 13.6% of body weight at 64 weeks, against 2.2% with placebo (205 and 102 participants). Gastrointestinal adverse events were more common with the medicine (74.0% vs 42.2%). The trial was funded by Novo Nordisk, which makes Wegovy.

What the four ads said and why the ASA upheld them

  • Voy bus poster (July 2026): a hand holding a white pill and the headline "The weight is over … voy", with small text saying "Glucomannan supplement" and the authorised glucomannan claim wording. Voy argued the headline was a play on words about not having to wait to lose weight. The ASA concluded that, given the image and the timing, people were likely to read it as meaning the wait for a GLP-1 tablet was over, and that the small text was not enough to change that impression.
  • Voy video-on-demand ad (seen 3 August 2026): a planet-like horizon, music from "2001: A Space Odyssey", the words "Oral weight support" over a close-up of a pill, and "It's kind of a small deal". Small text named a glucomannan supplement. The ASA said the build-up implied something new and significant, which viewers would link to the newly available GLP-1 tablets. It also noted that the website journey from the ad led to a page showing Wegovy and Mounjaro pens and tablets stamped "novo", and that none of the pages in that journey mentioned glucomannan.
  • Juniper YouTube ad (July 2026): white pills floating in the sky, "The weight loss pill is here", and caption text including "Over 92% of Members See Results in the First Month" and "No GP Referral Needed". Juniper said it had removed the ad in July. The ASA said many people would read it as promoting a prescription-only weight-loss medicine. A filtering page then led to a page naming the "Wegovy Pill".
  • MedExpress Instagram story (24 June 2026): a branded bottle of white pills with "New weight loss tablets", "Once daily pill", "No needles", "Coming soon" and "Join the waitlist". MedExpress said it had already withdrawn the ad. The ASA said the wording and image promoted a prescription-only medicine, and the landing page named the Wegovy pill and compared it with Wegovy and Mounjaro pens.

All four ads broke CAP Code rule 12.12, which says prescription-only medicines or prescription-only medical treatments may not be advertised to the public. The ASA told each company not to promote prescription-only medicines to the public in future. The Voy ads must not appear again in the form complained of, and the Juniper and MedExpress ads must not appear again in the form investigated. For both Voy ads, the ASA reported the MHRA's view that the design was "disingenuous" for trying to present the poster, or identify the video, as an ad for a non-medicinal product.

How the ASA decides an ad is for a prescription medicine

The rulings lean on consumer research the ASA published in April 2026. It found that people infer meaning from a combination of imagery, language, claims and overall presentation, so an ad can be read as promoting a weight-loss injection without naming one. The research also found that people are more likely to see these ads as encouraging a purchase than as prompting a conversation with a healthcare professional. The ASA noted that the research was carried out before oral weight-loss medicines were licensed in the UK, but treated its findings as still relevant.

CAP's advice to advertisers says almost every reference to a prescription-only medicine in traditional non-broadcast media, named or not, is treated as promotion of that medicine. The rulings also looked past the ad itself: where a link or a URL led people through a short series of pages to a named prescription medicine, that journey counted against the advertiser.

What glucomannan is and what it can claim

Glucomannan (konjac mannan) is a soluble fibre from the konjac plant. A 2026 systematic review generally associates its effects on fullness with its viscosity. The ASA notes it has been used in the UK for decades as a regulated food additive (E425). In 2010 the European Food Safety Authority gave a favourable scientific opinion on glucomannan and weight loss in the context of an energy-restricted diet. The resulting claim was authorised in Regulation 432/2012, which Great Britain retained, and authorised claims are listed on the Great Britain nutrition and health claims register.

The authorised claim comes with conditions. A food bearing it must contain 1 g of glucomannan per quantified portion, and the label must say the beneficial effect is obtained with 3 g a day, in three doses of 1 g, with 1 to 2 glasses of water before meals, in the context of an energy-restricted diet. The label must also carry a choking warning for people with swallowing difficulties or when taken with too little fluid, and advise taking it with plenty of water so it reaches the stomach.

What the trials show

  • Onakpoya and colleagues (J Am Coll Nutr, 2014) pooled 8 randomised trials in people with overweight or obesity and found no statistically significant difference in weight loss between glucomannan and placebo: a mean difference of -0.22 kg (95% confidence interval -0.62 to 0.19 kg). Reported side effects included abdominal discomfort, diarrhoea and constipation.
  • Bessell and colleagues (Int J Obes, 2021) found glucomannan users lost 1.27 kg more than placebo (95% CI -2.45 to -0.09 kg). That was statistically significant but below the authors' 2.5 kg threshold for clinical significance, and they concluded there was not enough evidence to recommend any of the supplements they reviewed for weight loss.
  • A 2023 network meta-analysis of 111 trials (Pharmacol Res) estimated 1.36 kg more weight loss with glucomannan than placebo (95% CI -2.17 to -0.54 kg), with low certainty of evidence.
  • In a randomised trial in 96 children and teenagers aged 6 to 17 with overweight or obesity (J Pediatr, 2019), 3 g a day for 12 weeks had no effect on BMI-for-age z score compared with placebo.
  • A 2026 dose-response meta-analysis of 11 trials in adults with insulin resistance-related conditions (Food Sci Nutr) found no significant effect on obesity indices. A 2026 systematic review in Food & Function found mixed results across 20 studies, many of them in animals, with several human studies reporting no effect.

The trial results are reported in different units, so a direct comparison is rough, but the gap is wide. The more favourable glucomannan analyses estimate a little over 1 kg more weight loss than placebo. In OASIS 4, the estimated mean change in body weight was -13.6% with oral semaglutide against -2.2% with placebo.

How to spot a supplement ad that looks like a medicine ad

  • Generic white pills or tablet imagery paired with words such as "new", "here", "no needles", "once daily" or "join the waitlist".
  • Eligibility language such as "check if you qualify" or "no GP referral needed", or claims about rapid or large weight loss. The ASA's research listed references to significant or rapid weight loss among signals of a weight-loss injection.
  • A supplement named only in small print, while the headline and imagery suggest something bigger.
  • A landing page that skips the supplement and leads to branded injection pens or tablets.

Our view

  • The rulings protect people who want the GLP-1 tablet as much as people who do not. A prescription decision should start with a clinical consultation, not an ad.
  • Glucomannan is lawful and authorised for a weight-loss claim in Great Britain, but the more favourable pooled estimates show a little over 1 kg more weight loss than placebo, and some analyses show none. Treat it as a fibre, not a pill that does what semaglutide does.
  • If you try glucomannan, follow the label: three 1 g doses a day, with 1 to 2 glasses of water before meals. The label warns of choking if you have swallowing difficulties or you take it with too little water.
  • If you are prescribed the semaglutide tablet, the MHRA says to take it whole on an empty stomach after fasting for at least 8 hours, with a sip of water, and wait at least 30 minutes before eating or drinking. Ask your pharmacist before adding any supplement around those timings.

UK rules and where to report

GLP-1 medicines, including the semaglutide tablet, are prescription-only. The MHRA says a private prescription must follow a consultation with a healthcare professional, that these medicines should not be bought from beauty salons, via social media or anywhere without a prior consultation, and that powder in vials to be mixed and injected is not an authorised product. You can check a Great Britain pharmacy on the General Pharmaceutical Council register, or a Northern Ireland pharmacy with the Pharmaceutical Society of Northern Ireland. Report a suspected side effect, or a medicine you think is not genuine, to the MHRA Yellow Card scheme.

Glucomannan supplements are regulated as food, not as medicines, and are not intended to treat or prevent disease. In England, Wales and Northern Ireland, report a food safety or hygiene problem to the local authority food safety team where the business is located. In England and Wales, report misleading labelling or health claims to Trading Standards. In Scotland and Northern Ireland, report those labelling and claims problems to the local food safety team. Anyone can complain to the ASA about an ad they think is misleading, harmful or promotes a prescription-only medicine.

FAQ

Is glucomannan a natural version of Wegovy?

No. Glucomannan is a soluble fibre sold as a food supplement. Semaglutide is a licensed medicine that mimics GLP-1, a hormone the body releases after eating, and acts on areas of the brain that regulate appetite. The trial results differ greatly in size.

Can I buy the Wegovy tablet without a prescription?

No. It is a prescription-only medicine. Private prescriptions require a consultation with a healthcare professional first, and the MHRA advises buying only from a registered pharmacy, including those trading online.

What happens to the ads now?

The ASA told each company not to promote prescription-only medicines to the public in future, and ruled that the Voy ads must not appear again in the form complained of, nor the Juniper and MedExpress ads in the form investigated.

Sources

These are the documents this page relies on.

  1. ASA Ruling on Menwell Ltd t/a Voy (poster), 4 November 2026Advertising Standards Authority
  2. ASA Ruling on Menwell Ltd t/a Voy (video on demand), 4 November 2026Advertising Standards Authority
  3. ASA Ruling on Juniper Technologies UK Ltd t/a Juniper, 4 November 2026Advertising Standards Authority
  4. ASA Ruling on MedExpress Enterprises Ltd t/a MedExpress, 4 November 2026Advertising Standards Authority
  5. How people interpret ads relating to prescription-only weight-loss medicines: summary, 2 April 2026Advertising Standards Authority
  6. Weight control: prescription-only medicines (AdviceOnline)Committee of Advertising Practice
  7. First GLP-1 tablet for weight loss approved in the UK, 11 June 2026Medicines and Healthcare products Regulatory Agency
  8. GLP-1 medicines for weight loss and diabetes: what you need to know (updated 5 February 2026)Medicines and Healthcare products Regulatory Agency
  9. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087New England Journal of Medicine (PubMed 40934115)
  10. EFSA NDA Panel. Scientific opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight. EFSA J. 2010;8(10):1798European Food Safety Authority
  11. Commission Regulation (EU) No 432/2012, Annex: list of permitted health claims (glucomannan entries), as retained in Great Britainlegislation.gov.uk
  12. Great Britain nutrition and health claims (NHC) registerDepartment of Health and Social Care
  13. Onakpoya I, Posadzki P, Ernst E. The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr. 2014;33(1):70-78Journal of the American College of Nutrition (PubMed 24533610)
  14. Bessell E, Maunder A, Lauche R, et al. Efficacy of dietary supplements containing isolated organic compounds for weight loss: a systematic review and meta-analysis of randomised placebo-controlled trials. Int J Obes. 2021;45(8):1631-1643International Journal of Obesity (PubMed 33976376)
  15. Shahinfar H, Jayedi A, Torabynasab K, et al. Comparative effects of nutraceuticals on body weight in adults with overweight or obesity: a systematic review and network meta-analysis of 111 randomized clinical trials. Pharmacol Res. 2023;196:106944Pharmacological Research (PubMed 37778464)
  16. Zalewski BM, Szajewska H. No effect of glucomannan on body weight reduction in children and adolescents with overweight and obesity: a randomized controlled trial. J Pediatr. 2019;211:85-91.e1Journal of Pediatrics (PubMed 31036412)
  17. Jazinaki MS, Rafiei H, Bahari H, Pahlavani N. Effects of glucomannan on cardiometabolic parameters in adults with insulin resistance-related conditions: a systematic review and dose-response meta-analysis. Food Sci Nutr. 2026;14(10):e72460Food Science & Nutrition (PubMed 42856808)
  18. Kusuma RA, Budiono I, Natasyaesa IA, et al. Glucomannan and resistant starch in obesity management: a systematic review of satiety, gut fermentation, and weight-related and metabolic outcomes. Food Funct. 2026;17(20):8941-8965Food & Function (PubMed 42765172)
  19. Make a complaintAdvertising Standards Authority
  20. Yellow Card schemeMedicines and Healthcare products Regulatory Agency
  21. Food supplementsFood Standards Agency
  22. How to report a food safety or hygiene issueFood Standards Agency
  23. Report misleading labellingFood Standards Agency